<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>心血管高季刊</title><link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U -NV u8003KrCpq8yLQC-&amp;ff=20230829100731&amp;fc=20230708114047&amp;v=2.17.9.post6+86293ac&amp;utm_source =镀铬<description>心血管高季刊：PubMed 的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20230829100731&amp;fc=20230708114047&amp;v=2.17.9.post6+86293ac&amp;utm_source=Chrome" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS 源 (2.17.9.post6+86293ac)</generator><language> zh</language><lastbuilddate> 2023 年 8 月 29 日星期二 14:07:33 +0000</lastbuilddate><pubDate> Tue, 29 Aug 2023 06:00:00 -0400</pubDate><ttl> 120</ttl><item><title> S14-磷酸化 RPN6 通过 PKA 介导蛋白酶体激活并减轻蛋白病</title><link/>https://pubmed.ncbi.nlm.nih.gov/37641975/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230829100731&amp;v=2.17.9.post6+86293ac<description>结论：本研究在动物中证实 pS14-Rpn6 通过 PKA 介导 26S 蛋白酶体的激活，并且减少的 pS14-Rpn6 是心脏蛋白病的关键致病因素，从而确定了减少心脏蛋白毒性的新治疗靶点。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 年 8 月 29 日。doi：10.1161/CIRCRESAHA.123.322887。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：更好地了解蛋白酶体活性的调节有助于寻找新的治疗策略。细胞培养研究表明，cAMP依赖性PKA（蛋白激酶A）通过pS14-Rpn6（丝氨酸14磷酸化Rpn6）激活26S蛋白酶体，但这一发现及其生理意义仍有待在体内确定。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：创建 Rpn6 Ser14 突变为 Ala (S14A [Rpn6/Psmd11 <sup>S14A</sup> ]) 或 Asp (S14D) 的雄性和雌性小鼠，分别阻断或模拟 pS14-Rpn6，并与源自它们的细胞一起使用。泛素-蛋白酶体系统功能通过 GFPdgn 报告小鼠和蛋白酶体活性测定进行评估。在过度表达错误折叠蛋白 R120G-CryAB (R120G) 的小鼠和心肌细胞中测试了 S14A 和 S14D 对蛋白毒性的影响。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：PKA 激活增加了野生型而非 S14A 胚胎成纤维细胞（小鼠胚胎成纤维细胞）、成年心肌细胞和小鼠心脏中的 pS14-Rpn6 和 26S 蛋白酶体活性。S14D 心肌和成年小鼠心肌细胞中的基础 26S 蛋白酶体活性显着高于对照组。与野生型对应物相比，S14D::GFPdgn 小鼠显示出比 GFPdgn 小鼠更低的心肌 GFPdgn 蛋白，但不显示 mRNA 水平。在 R120G 小鼠（心脏蛋白毒性的经典模型）中，与非转基因同窝小鼠相比，基础心肌 pS14-Rpn6 显着降低。与野生型新生儿心肌细胞相比，S14D 新生心肌细胞对 R120G 的蛋白酶体降解速度显着加快。与 R120G 小鼠相比，S14D/S14D::R120G 小鼠的心肌蛋白酶体活性显着增强，总泛素和 K48 连接泛素缀合物以及异常泛素缀合物水平较低。 CryAB蛋白聚集，胎儿基因再激活减少，心脏肥大，心脏功能障碍延迟。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：本研究在动物中证实 pS14-Rpn6 通过 PKA 介导 26S 蛋白酶体的激活，并且减少的 pS14-Rpn6 是心脏蛋白病的关键致病因素，从而确定了减少心脏蛋白毒性的新治疗靶点。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37641975/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829100731&v=2.17.9.post6+86293ac">37641975</a> | DOI： <a href=https://doi.org/10.1161/CIRCRESAHA.123.322887>10.1161/CIRCRESAHA.123.322887</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37641975</guid><pubDate> Tue, 29 Aug 2023 06:00:00 -0400</pubDate><dc:creator>杨柳青</dc:creator><dc:creator>尼尔玛·帕拉茹利</dc:creator><dc:creator>吴鹏龙</dc:creator><dc:creator>刘金宝</dc:creator><dc:creator>王学军更多</dc:creator><dc:date>2023-08-29</dc:date><dc:source>流通研究</dc:source><dc:title>S14-磷酸化 RPN6 通过 PKA 介导蛋白酶体激活并减轻蛋白病</dc:title><dc:identifier>下午：37641975</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.123.322887</dc:identifier></item><item><title>罕见变异遗传学和扩张型心肌病严重程度：DCM 精准医学研究</title><link/>https://pubmed.ncbi.nlm.nih.gov/37641966/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230829100731&amp;v=2.17.9.post6+86293ac<description>结论：与较不严重的 DCM 个体相比，晚期 DCM 与被判定为致病性或可能致病性的 DCM 基因中罕见变异的几率较高相关。这一发现可能有助于评估 DCM 患者及其高危患者管理中的结果风险。家庭成员。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 8 月 29 日。doi：10.1161/CIRCULATIONAHA.123.064847。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：扩张型心肌病 (DCM) 可导致晚期疾病，本文定义为需要耐用的左心室辅助装置或心脏移植 (LVAD/HT)。已知 DCM 具有遗传基础，但罕见变异遗传学与高级DCM尚未研究。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：我们分析了 2016 年至 2021 年美国多中心 DCM 精准医学研究中入组患者的临床和基因序列数据，该研究是一个地域多样、多种族、多民族的队列。临床评估包括标准化患者访谈和病历查询表。DCM 严重程度被分为 3 组：患有 LVAD/HT 的晚期疾病患者；仅植入式心律转复除颤器 (ICD) 的患者；或无 ICD 或 LVAD/HT 的患者。36 个 DCM 基因中的罕见变异被分类为致病性或可能致病性或我们考虑的混杂因素包括人口特征、生活方式因素、获得护理的机会、DCM 持续时间和合并症。使用具有广义 Logit 关联的多项模型评估 DCM 严重程度与罕见变异遗传结果之间的粗略和调整关联。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：患者的平均 (SD) 年龄为 51.9 (13.6) 岁；42% 为非洲血统，56% 为欧洲血统，44% 为女性。1198 名患者中，347 名患有 LVAD/HT，511 名患有 ICD对于 LVAD/HT、仅 ICD 或两者都没有的患者，具有致病性或可能致病性变异的患者比例分别为 26.2%、15.9% 和 15.0%。那些没有 LVAD/HT 或 ICD 的患者具有与 DCM 相关的致病性或可能致病性罕见变异（比值比，2.3 [95% CI，1.5–3.6]）。相关性并没有因血统而异。罕见变异的遗传发现在患有 DCM 的患者之间相似。带 ICD 的 DCM 和不带 LVAD/HT 或 ICD 的 DCM。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：与较不严重的 DCM 个体相比，晚期 DCM 与被判定为致病性或可能致病性的 DCM 基因中罕见变异的几率较高相关。这一发现可能有助于评估 DCM 患者及其高危患者管理中的结果风险。家庭成员。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">注册：网址：https://www. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">临床试验：gov；唯一标识符：NCT03037632。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37641966/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829100731&v=2.17.9.post6+86293ac">37641966</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064847>10.1161 / CIRCULATIONAHA.123.064847</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37641966</guid><pubDate> Tue, 29 Aug 2023 06:00:00 -0400</pubDate><dc:creator>马克·霍夫迈尔</dc:creator><dc:creator>加里·J·哈斯</dc:creator><dc:creator>伊丽莎白乔丹</dc:creator><dc:creator>曹金文</dc:creator><dc:creator>埃文·克兰斯多夫</dc:creator><dc:creator>——格雷戈里·A·埃瓦尔德</dc:creator><dc:creator>阿兰娜·莫里斯</dc:creator><dc:creator>安贾利·欧文斯</dc:creator><dc:creator>布赖恩·洛斯</dc:creator><dc:creator>道格拉斯·斯托勒</dc:creator><dc:creator>WH 邓伟逊</dc:creator><dc:creator>索尼娅·加尔格</dc:creator><dc:creator>巴里·特拉亨伯格</dc:creator><dc:creator>帕拉克·沙阿</dc:creator><dc:creator>萨尔皮 V 庞布基安</dc:creator><dc:creator>南希·K·斯威策</dc:creator><dc:creator>——马修·T·惠勒</dc:creator><dc:creator>简·E·威尔科克斯</dc:creator><dc:creator>——斯图尔特·卡茨</dc:creator><dc:creator>斯蒂芬·潘</dc:creator><dc:creator>哈维尔希门尼斯</dc:creator><dc:creator>弗兰克·斯马特</dc:creator><dc:creator>——王杰西卡</dc:creator><dc:creator>斯蒂芬·戈特利布</dc:creator><dc:creator>丹尼尔·P·贾吉</dc:creator><dc:creator>查尔斯·K·摩尔</dc:creator><dc:creator>——戈登·S·哈金斯</dc:creator><dc:creator>丹尼尔·D·金纳蒙</dc:creator><dc:creator>倪瀚宇</dc:creator><dc:creator>雷·E·赫什伯格</dc:creator><dc:creator>DCM联盟的DCM精准医学研究</dc:creator><dc:date>2023-08-29</dc:date><dc:source>循环</dc:source><dc:title>罕见变异遗传学和扩张型心肌病严重程度：DCM 精准医学研究</dc:title><dc:identifier>下午：37641966</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.064847</dc:identifier></item><item><title>运动期间心脏迷走神经活动增加，以增强冠状动脉血流量</title><link/>https://pubmed.ncbi.nlm.nih.gov/37641938/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230829100731&amp;v=2.17.9.post6+86293ac<description>结论：我们的研究表明，心脏迷走神经活动实际上会增加，对于运动期间维持心脏功能至关重要。此外，我们的研究结果表明，运动期间冠状动脉血流的动态调节是由 VIP 介导的。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 年 8 月 29 日。doi：10.1161/CIRCRESAHA.123.323017。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：在讨论运动过程中心脏的自主控制时，经常使用“迷走神经完全撤退”这个词。然而，最近的研究对这一假设提出了挑战。我们假设心脏迷走神经活动在运动过程中增加，并通过乙酰胆碱以外的递质维持心脏功能。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：对清醒的成年羊进行全身跑步机运动时，长期直接记录心脏迷走神经活动、心输出量、冠状动脉血流量和心率。用亲脂性示踪染料证实左心迷走神经分支的心脏神经支配。 DiO）。用乙酰胆碱药物阻断剂（阿托品，250 mg）、VIP（血管活性肠肽；[4Cl-D-Phe6，Leu17] VIP 25 µg）或盐水对照对绵羊进行锻炼，在不同的日子随机进行。左心脏迷走神经分支被去神经支配。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在主要心脏神经节丛以及与冠状动脉相关的脂肪垫内可以看到来自心脏迷走神经分支的神经支配。直接记录的心脏迷走神经活动在运动期间增加。左心脏迷走神经分支去神经减弱了冠状动脉的最大变化血流量（最大运动，对照：63.5±5.9 mL/min，n=8；心脏迷走神经去神经：32.7±5.6 mL/min，n=6， <i>P=</i> 2.5×10 <sup>-</sup> <sup>7</sup> ）、心输出量和心率阿托品不会影响运动期间的任何心脏参数，但 VIP 拮抗作用显着降低运动期间的冠状动脉血流量，达到与迷走神经去神经术相似的水平。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：我们的研究表明，心脏迷走神经活动实际上会增加，对于运动期间维持心脏功能至关重要。此外，我们的研究结果表明，运动期间冠状动脉血流的动态调节是由 VIP 介导的。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37641938/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829100731&v=2.17.9.post6+86293ac">37641938</a> | DOI： <a href=https://doi.org/10.1161/CIRCRESAHA.123.323017>10.1161/CIRCRESAHA.123.323017</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37641938</guid><pubDate> Tue, 29 Aug 2023 06:00:00 -0400</pubDate><dc:creator>朱莉娅·香克斯</dc:creator><dc:creator>姆里杜拉·帕钦</dc:creator><dc:creator>张伟华</dc:creator><dc:creator>宾杜·乔治更多</dc:creator><dc:creator>罗希特·拉姆钱德拉</dc:creator><dc:date>2023-08-29</dc:date><dc:source>流通研究</dc:source><dc:title>运动期间心脏迷走神经活动增加，以增强冠状动脉血流量</dc:title><dc:identifier>下午：37641938</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.123.323017</dc:identifier></item><item><title>中性粒细胞血运重建需要 TNFα 激活 CCR6 和 CCL20</title><link/> https://pubmed.ncbi.nlm.nih.gov/37641931/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230829100731&amp;v=2.17.9.post6+86293ac<description>结论：我们证明，通过 TNFα 对 CCL20-CCR6 轴进行位点特异性激活，可将表达促血管生成 VEGFA 的中性粒细胞募集到缺血性损伤部位，从而启动肌肉组织血运重建。这些发现为组织血运重建提供了一个有吸引力的选择，特别是在糖尿病条件下。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 年 8 月 29 日。doi：10.1161/CIRCRESAHA.123.323071。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：涉及 TNFα（肿瘤坏死因子 α）信号传导的免疫炎症途径的激活对于缺血性损伤后的血运重建和外周肌肉组织修复至关重要。尚不清楚。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：通过激光多普勒成像和光片荧光显微镜监测突变小鼠永久股动脉结扎后的肌肉组织血运重建。TNFα介导的信号传导和CCL20（CC基序趋化因子配体20）-CCR6（CC趋化因子受体6）的作用使用骨髓移植、流式细胞术以及生化和分子生物学技术在体外和体内研究了新血管形成的轴。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：发现TNFα介导的肿瘤坏死因子受体TNFR（肿瘤坏死因子受体）1而非TNFR2的激活是缺血后肌肉组织血运重建所必需的。骨髓来源的CCR6 <sup>+</sup>中性粒细胞被鉴定为先前未描述的TNFα诱导的促血管生成中性粒细胞群，其特征是 VEGFA（血管内皮生长因子 A）表达增加。表达 VEGFA 的促血管生成中性粒细胞依赖 CCL20 募集到缺血部位。改善糖尿病缺血骨骼肌的血运重建，通过氟伐他汀序贯治疗得以维持。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：我们证明，通过 TNFα 对 CCL20-CCR6 轴进行位点特异性激活，可将表达促血管生成 VEGFA 的中性粒细胞募集到缺血性损伤部位，从而启动肌肉组织血运重建。这些发现为组织血运重建提供了一个有吸引力的选择，特别是在糖尿病条件下。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37641931/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829100731&v=2.17.9.post6+86293ac">37641931</a> | DOI： <a href=https://doi.org/10.1161/CIRCRESAHA.123.323071>10.1161/CIRCRESAHA.123.323071</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37641931</guid><pubDate> Tue, 29 Aug 2023 06:00:00 -0400</pubDate><dc:creator>霍尔格·洛希纳</dc:creator><dc:creator>莱娅·卡内斯·埃斯特夫</dc:creator><dc:creator>玛丽亚·埃莉莎去</dc:creator><dc:creator>罗克珊·哈泽内特</dc:creator><dc:creator>娜塔莉·布拉克曼</dc:creator><dc:creator>普拉文·加贾瓦达</dc:creator><dc:creator>斯特凡·冈瑟</dc:creator><dc:creator>尼古拉斯·多尔</dc:creator><dc:creator>约亨·珀林</dc:creator><dc:creator>托马斯·布劳恩</dc:creator><dc:date>2023-08-29</dc:date><dc:source>流通研究</dc:source><dc:title>中性粒细胞血运重建需要 TNFα 激活 CCR6 和 CCL20</dc:title><dc:identifier>下午：37641931</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.123.323071</dc:identifier></item><item><title>降脂治疗后冠状动脉粥样硬化的消退和稳定</title><link/>https://pubmed.ncbi.nlm.nih.gov/37640248/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230829100731&amp;v=2.17.9.post6+86293ac<description>结论：三分之一接受高强度降脂治疗的 AMI 患者出现三重回归，并且与 alirocumab 治疗、较高的基线脂质含量和减少的心血管事件相关。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 8 月 20 日：S0735-1097(23)06468-9。doi：10.1016/j.jacc.2023.08.019。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：接受高强度降脂治疗并同时出现粥样斑块体积减少、脂质含量减少和纤维帽厚度增加（即“三重回归”）的患者的频率、特征和结果尚不清楚。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：本研究旨在调查急性心肌梗死 (AMI) 并接受高强度降脂治疗的患者三重回归的发生率、决定因素和预后影响。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：PACMAN-AMI 试验采用连续血管内超声、近红外光谱和光学相干断层扫描来比较 alirocumab 与安慰剂在接受高强度他汀类药物治疗的患者中的效果。三重回归是通过动脉粥样硬化百分比的组合存在来定义的体积 (PAV) 减少、最大脂质核心负荷指数 4 毫米以内 (maxLCBI <sub>4mm</sub> ) 减少、最小纤维帽厚度 (FCT) 增加。评估一年随访时的临床结果。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：总体而言，84 名患者 (31.7%) 出现三重回归（alirocumab 组为 40.8%，安慰剂组为 23.0%，p=0.002）。无三重回归（组间差异 -27.1 [-37.7 至 -16.6] mg/dl，p&lt;0.001）。三重回归由 alirocumab 治疗独立预测（比值比 [OR] 2.83，95% 置信区间 [CI] 1.57-5.16，p=0.001）和更高的基线 maxLCBI <sub>4 mm</sub> （OR 1.03，95%CI 1.01-1.06，p=0.013）。与没有三重回归的情况相比（8.3% 与 18.2%，p=0.04）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：三分之一接受高强度降脂治疗的 AMI 患者出现三重回归，并且与 alirocumab 治疗、较高的基线脂质含量和减少的心血管事件相关。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37640248/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829100731&v=2.17.9.post6+86293ac">37640248</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.08.019>10.1016/j.jacc.2023.08.019</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37640248</guid><pubDate> Mon, 28 Aug 2023 06:00:00 -0400</pubDate><dc:creator>弗拉维奥·G·比西雷</dc:creator><dc:creator>乔纳斯·汉纳</dc:creator><dc:creator>西尔万·洛斯达特</dc:creator><dc:creator>植木靖</dc:creator><dc:creator>涉谷宏树</dc:creator><dc:creator>大冢达彦</dc:creator><dc:creator>柿崎良太</dc:creator><dc:creator>托马斯·霍夫鲍尔</dc:creator><dc:creator>罗伯特·扬·范格恩斯</dc:creator><dc:creator>斯特凡·斯托特基</dc:creator><dc:creator>乔治斯·西昂蒂斯</dc:creator><dc:creator>莎拉·巴尔</dc:creator><dc:creator>雅各布·伦伯格</dc:creator><dc:creator>迪克·赫格</dc:creator><dc:creator>克里斯托夫·凯撒</dc:creator><dc:creator>大卫·斯皮克</dc:creator><dc:creator>乔斯特·戴门</dc:creator><dc:creator>胡安·伊格莱西亚斯</dc:creator><dc:creator>史蒂芬·温德克</dc:creator><dc:creator>托马斯·恩斯特罗姆</dc:creator><dc:creator>艾琳·朗</dc:creator><dc:creator>康斯坦丁诺斯·C·科斯基纳斯</dc:creator><dc:creator>洛伦兹·拉贝尔</dc:creator><dc:date>2023-08-28</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>降脂治疗后冠状动脉粥样硬化的消退和稳定</dc:title><dc:identifier>下午：37640248</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.08.019</dc:identifier></item><item><title>什么是正常左心室射血分数？</title><link/> https://pubmed.ncbi.nlm.nih.gov/37639509/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230829100731&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 8 月 29 日；148(9):750-752. doi: 10.1161/CIRCULATIONAHA.123.065791. Epub 2023 年 8 月 28 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37639509/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829100731&v=2.17.9.post6+86293ac">37639509</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065791>10.1161 / CIRCULATIONAHA.123.065791</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37639509</guid><pubDate> Mon, 28 Aug 2023 06:00:00 -0400</pubDate><dc:creator>保罗·海登赖希</dc:creator><dc:date>2023-08-28</dc:date><dc:source>循环</dc:source><dc:title>什么是正常左心室射血分数？</dc:title><dc:identifier>下午：37639509</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.065791</dc:identifier></item><item><title> Ostadal 和 Belohlavek 对有关文章“心源性休克治疗中的体外膜氧合：ECMO-CS 随机临床试验的结果”的信件的回应</title><link/>https://pubmed.ncbi.nlm.nih.gov/37639508/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230829100731&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 8 月 29 日；148(9):804.doi: 10.1161/CIRCULATIONAHA.123.065358. Epub 2023 年 8 月 28 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37639508/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829100731&v=2.17.9.post6+86293ac">37639508</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065358>10.1161/CIRCULATIONAHA.123.065358</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37639508</guid><pubDate> Mon, 28 Aug 2023 06:00:00 -0400</pubDate><dc:creator>彼得·奥斯塔达尔更多</dc:creator><dc:creator>扬·贝洛拉维克</dc:creator><dc:date>2023-08-28</dc:date><dc:source>循环</dc:source><dc:title>Ostadal 和 Belohlavek 对有关文章“心源性休克治疗中的体外膜氧合：ECMO-CS 随机临床试验的结果”的信件的回应</dc:title><dc:identifier>下午：37639508</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.065358</dc:identifier></item><item><title> Ferreira 关于文章“心源性休克治疗中的体外膜氧合：ECMO-CS 随机临床试验的结果”的信函</title><link/>https://pubmed.ncbi.nlm.nih.gov/37639506/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230829100731&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 8 月 29 日；148(9):803. doi: 10.1161/CIRCULATIONAHA.122.063622. Epub 2023 年 8 月 28 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37639506/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829100731&v=2.17.9.post6+86293ac">37639506</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.122.063622>10.1161/CIRCULATIONAHA.122.063622</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37639506</guid><pubDate> Mon, 28 Aug 2023 06:00:00 -0400</pubDate><dc:creator>豪尔赫·费雷拉</dc:creator><dc:date>2023-08-28</dc:date><dc:source>循环</dc:source><dc:title>Ferreira 关于文章“心源性休克治疗中的体外膜氧合：ECMO-CS 随机临床试验的结果”的信函</dc:title><dc:identifier>下午：37639506</dc:identifier><dc:identifier> doi:10.1161/循环AHA.122.063622</dc:identifier></item><item><title>消除医学中结构性种族主义的阶段：关注医学培训</title><link/>https://pubmed.ncbi.nlm.nih.gov/37639505/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230829100731&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 8 月 29 日；148(9):800-802.doi: 10.1161/CIRCULATIONAHA.123.066131. ​​Epub 2023 年 8 月 28 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37639505/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829100731&v=2.17.9.post6+86293ac">37639505</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066131>10.1161 / CIRCULATIONAHA.123.066131</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37639505</guid><pubDate> Mon, 28 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Nisha Donthi更多</dc:creator><dc:creator>凯瑟琳·R·露西</dc:creator><dc:creator>米歇尔·阿尔伯特</dc:creator><dc:date>2023-08-28</dc:date><dc:source>循环</dc:source><dc:title>消除医学中结构性种族主义的阶段：关注医学培训</dc:title><dc:identifier>下午：37639505</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.066131</dc:identifier></item><item><title>高收入、中等收入和低收入国家心力衰竭患者的虚弱和结局</title><link/>https://pubmed.ncbi.nlm.nih.gov/37639487/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230829100731&amp;v=2.17.9.post6+86293ac<description>结论：虚弱为预测死亡和心衰住院的预后变量提供了大量增量预后信息。虚弱与这些结果之间的关系在所有收入水平的国家中都是一致的。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 28 日：ehad595。doi：10.1093/eurheartj/ehad595。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目的：除了来自不同国家收入水平的心力衰竭（HF）人群的传统预后变量之外，关于衰弱的增量预后重要性的信息很少。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：对来自 27 个高、中、低收入国家的 3429 名心力衰竭成人（年龄 61±14 岁，33% 女性）进行前瞻性研究。活动、意外体重减轻和自我报告的疲惫。平均左心室射血分数为 39±14%，26% 具有纽约心脏协会 (NYHA) III/IV 级症状。对参与者进行中位数（第 25-75 个百分位数）跟踪3.1（2.0-4.3）年。根据国家收入水平、年龄、性别、教育、使用、血压、血红蛋白、钠和肌酐浓度调整了死亡和心力衰竭住院的Cox比例风险模型。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在基线时，18% 的参与者身体健康，61% 的参与者处于虚弱状态，21% 的参与者虚弱。在随访期间，565 名参与者 (16%) 死亡，471 名参与者 (14%) 因心力衰竭住院。各自调整后的风险比 [衰弱前和衰弱者死亡的 HR (95% CI)] 分别为 1.59 (1.12-2.26) 和 2.92 (1.99-4.27)。1.33-2.91)。不同收入水平国家和大多数亚组的研究结果是一致的。 MAGGIC 风险评分改善了对未来死亡和心力衰竭住院治疗的区分。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：虚弱为预测死亡和心衰住院的预后变量提供了大量增量预后信息。虚弱与这些结果之间的关系在所有收入水平的国家中都是一致的。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37639487/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829100731&v=2.17.9.post6+86293ac">37639487</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad595>10.1093/eurheartj/ehad595</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37639487</guid><pubDate> Mon, 28 Aug 2023 06:00:00 -0400</pubDate><dc:creator>达里尔·P·梁</dc:creator><dc:creator>菲利普·约瑟夫</dc:creator><dc:creator>约翰·JV·麦克默里</dc:creator><dc:creator>让·鲁洛</dc:creator><dc:creator>阿尔多·P·马吉奥尼</dc:creator><dc:creator>费尔南多·拉纳斯</dc:creator><dc:creator>桑吉布·K·夏尔马 (Sanjib K Sharma)</dc:creator><dc:creator>胡里奥·努涅斯</dc:creator><dc:creator>比沙夫·莫汉</dc:creator><dc:creator>艾哈迈德·塞利克</dc:creator><dc:creator>贾比尔·阿卜杜拉库蒂</dc:creator><dc:creator>奥克丘库·S·奥加</dc:creator><dc:creator>丽莎·米尔尼祖克</dc:creator><dc:creator>库马尔·巴拉苏布拉曼尼安</dc:creator><dc:creator>塔拉·麦克雷迪</dc:creator><dc:creator>——亚历克斯·格林瓦尔兹</dc:creator><dc:creator>萨利姆·优素福</dc:creator><dc:creator>P约瑟夫</dc:creator><dc:creator>G-CHF 研究人员</dc:creator><dc:date>2023-08-28</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>高收入、中等收入和低收入国家心力衰竭患者的虚弱和结局</dc:title><dc:identifier>下午：37639487</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad595</dc:identifier></item><item><title>第三代 PCSK9 抑制剂</title><link/>https://pubmed.ncbi.nlm.nih.gov/37639486/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230829100731&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 28 日：ehad566。doi：10.1093/eurheartj/ehad566。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37639486/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829100731&v=2.17.9.post6+86293ac">37639486</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad566>10.1093/eurheartj/ehad566</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37639486</guid><pubDate> Mon, 28 Aug 2023 06:00:00 -0400</pubDate><dc:creator>乌尔里希·劳夫斯</dc:creator><dc:creator>马蒂亚斯·布吕赫</dc:creator><dc:creator>贝伦德·伊瑟曼</dc:creator><dc:date>2023-08-28</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>第三代 PCSK9 抑制剂</dc:title><dc:identifier>下午：37639486</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad566</dc:identifier></item><item><title> Emery-Dreifuss 型肌营养不良症 1 与恶性室性心律失常和终末期心力衰竭的高风险相关</title><link/>https://pubmed.ncbi.nlm.nih.gov/37639473/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230829100731&amp;v=2.17.9.post6+86293ac<description>结论：男性EMD变异携带者发生进行性心力衰竭和室性心律失常的风险与男性LMNA变异携带者相似，对于患有心脏病的男性EMD变异携带者应考虑早期植入式心脏复律除颤器植入和心力衰竭药物治疗。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 28 日：ehad561。doi：10.1093/eurheartj/ehad561。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目的：Emery-Dreifuss 肌营养不良症 (EDMD) 是由 EMD (EDMD1) 和 LMNA (EDMD2) 变异引起的。心脏传导缺陷和房性心律失常对两者都很常见，但 LMNA 变异也会导致终末期心力衰竭 (ESHF) ）和恶性室性心律失常（MVA）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：从 12 个国际心肌病病房回顾性招募连续转介的 EMD 变异携带者。确定男性和女性变异携带者的 MVA 和 ESHF 发生率。将基线时具有心脏表型 (EMDCARDIAC) 的男性 EMD 变异携带者与连续招募的患者进行比较基线时具有心脏表型的男性 LMNA 变异携带者 (LMNACARDIAC)。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：获得了 38 名男性和 21 名女性 EMD 变异携带者的纵向随访数据（平均 [SD] 年龄分别为 33.4 [13.3] 和 43.3 [16.8] 岁）。九名 (23.6%) 男性出现 MVA，五名 ( 13.2%）在中位 [IQR] 随访期间 [IQR] 65.0 [24.3, 109.5] 个月出现 ESHF。没有女性 EMD 变异携带者患有 MVA 或 ESHF，但 9 名 (42.8%) 在中位 [IQR] 时出现心脏表型年龄为 58.6 [53.2, 60.4] 岁。EMDCARDIAC 和 LMNACARDIAC 的 MVA 发病率相似（分别为每 100 人年 4.8 和 6.6；对数秩 p = 0.49）。ESHF 的发病率为每 100 人 2.4 和 5.9 EMDCARDIAC 和 LMNACARDIAC 分别为人年（对数秩 p = 0.09）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：男性EMD变异携带者发生进行性心力衰竭和室性心律失常的风险与男性LMNA变异携带者相似，对于患有心脏病的男性EMD变异携带者应考虑早期植入式心脏复律除颤器植入和心力衰竭药物治疗。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37639473/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829100731&v=2.17.9.post6+86293ac">37639473</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad561>10.1093/eurheartj/ehad561</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37639473</guid><pubDate> Mon, 28 Aug 2023 06:00:00 -0400</pubDate><dc:creator>道格拉斯·E·坎尼</dc:creator><dc:creator>彼得罗斯·西里斯</dc:creator><dc:creator>亚历山德罗斯·普罗托塔里奥斯</dc:creator><dc:creator>阿塔纳西奥斯·巴卡拉科斯</dc:creator><dc:creator>让-弗朗索瓦·普鲁尼</dc:creator><dc:creator>拉斐尔·迪塔兰托</dc:creator><dc:creator>克里斯蒂娜·马丁内斯·维拉</dc:creator><dc:creator>何塞·M·拉拉纳加-莫雷拉</dc:creator><dc:creator>克里斯汀·梅多</dc:creator><dc:creator>弗朗西斯科·何塞·贝穆德斯-希门尼斯</dc:creator><dc:creator>拉巴·本·亚乌</dc:creator><dc:creator>法国勒图尔克</dc:creator><dc:creator>艾尼霍亚·罗伯斯·梅斯库亚</dc:creator><dc:creator>基亚拉·马里尼·贝托洛</dc:creator><dc:creator>伊娃·卡布雷拉</dc:creator><dc:creator>克洛伊路透社</dc:creator><dc:creator>哈维尔·利梅雷斯·弗莱雷</dc:creator><dc:creator>何塞·F·罗德里格斯-帕洛马雷斯</dc:creator><dc:creator>路易莎·梅斯特罗尼</dc:creator><dc:creator>——马修·R·G·泰勒</dc:creator><dc:creator>维多利亚·N·帕里克</dc:creator><dc:creator>尤安·阿什利</dc:creator><dc:creator>罗伯托·巴里亚莱斯-维拉</dc:creator><dc:creator>胡安·希门尼斯·雅梅斯</dc:creator><dc:creator>巴勃罗·加西亚-帕维亚</dc:creator><dc:creator>菲利普·查伦</dc:creator><dc:creator>埃琳娜·比亚吉尼</dc:creator><dc:creator>何塞·M·加西亚·皮尼利亚</dc:creator><dc:creator>约翰·伯克</dc:creator><dc:creator>康斯坦丁诺斯·萨瓦蒂斯</dc:creator><dc:creator>卡里姆·瓦赫比</dc:creator><dc:creator>佩里·埃利奥特</dc:creator><dc:date>2023-08-28</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>Emery-Dreifuss 型肌营养不良症 1 与恶性室性心律失常和终末期心力衰竭的高风险相关</dc:title><dc:identifier>下午：37639473</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad561</dc:identifier></item><item><title>虚弱：心力衰竭的新生命体征成熟</title><link/>https://pubmed.ncbi.nlm.nih.gov/37639470/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230829100731&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 28 日：ehad559。doi：10.1093/eurheartj/ehad559。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37639470/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829100731&v=2.17.9.post6+86293ac">37639470</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad559>10.1093/eurheartj/ehad559</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37639470</guid><pubDate> Mon, 28 Aug 2023 06:00:00 -0400</pubDate><dc:creator>芬利·麦卡利斯特</dc:creator><dc:date>2023-08-28</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>虚弱：心力衰竭的新生命体征成熟</dc:title><dc:identifier>下午：37639470</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad559</dc:identifier></item><item><title> lerodalcibep 对杂合子家族性高胆固醇血症的长期疗效和安全性：LIBERate-HeFH 试验</title><link/>https://pubmed.ncbi.nlm.nih.gov/37639462/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230829100731&amp;v=2.17.9.post6+86293ac<description>结论：Lerodalcibep 是一种新型抗 PCSK9 小结合蛋白，每月给药一次，作为单克隆抗体的替代品，可显着降低 HeFH 受试者的 LDL-C，且安全性与安慰剂相似。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 28 日：ehad596。doi：10.1093/eurheartj/ehad596。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目标：Lerodalcibep 是一种由 PCSK9 结合域（adnectin）和人血清白蛋白组成的新型小型重组融合蛋白，每月 300 mg 1.2 ml SC 剂量阶段性证明可高效降低低密度脂蛋白胆固醇（LDL-C） 2. 在这项全球 3 期试验中，在需要额外降低 LDL-C 的杂合子家族性高胆固醇血症 (HeFH) 患者中评估了 lerodalcibep 的安全性和有效性。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：患者以 2:1 的比例随机分组，每月皮下注射 lerodalcibep 300 mg 或安慰剂，持续 24 周。主要疗效终点是第 24 周时 LDL-C 相对于基线的百分比变化以及第 22 周和第 24 周的平均值。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在 478 名随机受试者中[平均年龄（范围）；53 (18-80) 岁，51.7% 女性，平均 (SD) 基线 LDL-C 3.88 (1.66) mmol/L] 与安慰剂相比，lerodalcibep 降低了 LDL-C绝对量为 2.08 (0.11) mmol/L [LS 平均值 (SE)；95% CI -2.30 至 -1.87]，第 24 周时的百分比差异为 -58.61 (3.25)%，增加 2.28 (0.10) mmol/ L L (95% CI -2.47 至 -2.09)，第 22 周和第 24 周的平均值百分比差异为 -65.0 (2.87)%（所有 P &lt; 0.0001）。使用 lerodalcibep，68% 的受试者实现了降低研究期间 LDL-C ≥ 50% 和推荐的 ESC LDL-C 目标。除了轻微的注射部位反应外，lerodalcibep 和安慰剂之间治疗引起的不良事件相似。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：Lerodalcibep 是一种新型抗 PCSK9 小结合蛋白，每月给药一次，作为单克隆抗体的替代品，可显着降低 HeFH 受试者的 LDL-C，且安全性与安慰剂相似。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37639462/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829100731&v=2.17.9.post6+86293ac">37639462</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad596>10.1093/eurheartj/ehad596</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37639462</guid><pubDate> Mon, 28 Aug 2023 06:00:00 -0400</pubDate><dc:creator>弗雷德里克·拉尔</dc:creator><dc:creator>尼达·福里</dc:creator><dc:creator>拉塞尔·斯科特</dc:creator><dc:creator>德克·布洛姆</dc:creator><dc:creator>马蒂斯·德弗里斯·巴松</dc:creator><dc:creator>梅拉尔·卡伊克吉奥卢</dc:creator><dc:creator>——凯特·考德威尔</dc:creator><dc:creator>大卫·卡伦德</dc:creator><dc:creator>埃文·斯坦因</dc:creator><dc:creator>LIBerate-HeFH 调查人员</dc:creator><dc:date>2023-08-28</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>lerodalcibep 对杂合子家族性高胆固醇血症的长期疗效和安全性：LIBERate-HeFH 试验</dc:title><dc:identifier>下午：37639462</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad596</dc:identifier></item><item><title> Mavacamten 对有症状的梗阻性肥厚型心肌病患者的长期疗效和安全性</title><link/>https://pubmed.ncbi.nlm.nih.gov/37639276/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230829100731&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol. 2023 Aug 28. doi: 10.1001/jamacardio.2023.3357. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37639276/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829100731&v=2.17.9.post6+86293ac">37639276</a> | DOI: <a href=https://doi.org/10.1001/jamacardio.2023.3357>10.1001/jamacardio.2023.3357</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37639276</guid><pubDate> Mon, 28 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Sharlene M Day</dc:creator><dc:creator> James E Udelson</dc:creator><dc:creator> Robert O Bonow</dc:creator><dc:date> 2023-08-28</dc:date><dc:source> JAMA cardiology</dc:source><dc:title> Long-Term Efficacy and Safety of Mavacamten in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy</dc:title><dc:identifier> pmid:37639276</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.3357</dc:identifier></item><item><title> Mavacamten for Obstructive Hypertrophic Cardiomyopathy in China</title><link/> https://pubmed.ncbi.nlm.nih.gov/37639265/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230829100731&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol. 2023 Aug 28. doi: 10.1001/jamacardio.2023.3045. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37639265/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829100731&v=2.17.9.post6+86293ac">37639265</a> | DOI: <a href=https://doi.org/10.1001/jamacardio.2023.3045>10.1001/jamacardio.2023.3045</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37639265</guid><pubDate> Mon, 28 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Milind Y Desai</dc:creator><dc:date> 2023-08-28</dc:date><dc:source> JAMA cardiology</dc:source><dc:title> Mavacamten for Obstructive Hypertrophic Cardiomyopathy in China</dc:title><dc:identifier> pmid:37639265</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.3045</dc:identifier></item><item><title> Effect of Mavacamten on Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy: The EXPLORER-CN Randomized Clinical Trial</title><link/> https://pubmed.ncbi.nlm.nih.gov/37639259/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230829100731&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: Mavacamten significantly improved Valsalva LVOT gradient vs placebo for Chinese patients. All secondary efficacy end points were also improved. Mavacamten was well tolerated with no new safety signals. This study supports the efficacy and safety of mavacamten in diverse populations, including Chinese patients. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol. 2023 Aug 28. doi: 10.1001/jamacardio.2023.3030. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> IMPORTANCE: Mavacamten has shown clinical benefits in global studies for patients with obstructive hypertrophic cardiomyopathy (oHCM), but evidence in the Asian population is lacking. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> OBJECTIVE: To evaluate the safety and efficacy of mavacamten compared with placebo for Chinese patients with symptomatic oHCM. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> DESIGN, SETTING, AND PARTICIPANTS: This phase 3, randomized, double-blind, placebo-controlled clinical trial was conducted at 12 hospitals in China. Between January 4 and August 5, 2022, patients with oHCM and a left ventricular outflow tract (LVOT) gradient of 50 mm Hg or more and New York Heart Association (NYHA) class II or III symptoms were enrolled and received treatment for 30 weeks. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> INTERVENTIONS: Patients were randomized 2:1 to receive mavacamten (starting at 2.5 mg once daily) or placebo for 30 weeks. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> MAIN OUTCOMES AND MEASURES: The primary end point was change in Valsalva LVOT peak gradient from baseline to week 30. Left ventricular outflow tract gradients and left ventricular ejection fraction (LVEF) were assessed by echocardiography, while left ventricular mass index (LVMI) was determined by cardiac magnetic resonance imaging. Analysis was performed on an intention-to-treat basis. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: A total of 81 patients (mean [SD] age, 51.9 [11.9] years; 58 men [71.6%]) were randomized. Mavacamten demonstrated a significant improvement in the primary end point compared with placebo (least-squares mean [LSM] difference, -70.3 mm Hg; 95% CI, -89.6 to -50.9 mm Hg; 1-sided P &lt; .001). Similar trends were demonstrated for resting LVOT peak gradient (LSM difference, -55.0 mm Hg; 95% CI, -69.1 to -40.9 mm Hg). At week 30, more patients receiving mavacamten than placebo achieved a Valsalva LVOT peak gradient less than 30 mm Hg (48.1% [26 of 54] vs 3.7% [1 of 27]), less than 50 mm Hg (59.3% [32 of 54] vs 7.4% [2 of 27]), and NYHA class improvement (59.3% [32 of 54] vs 14.8% [4 of 27]). Greater improvements were also observed with mavacamten regarding the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (LSM difference, 10.2; 95% CI, 4.4-16.1), N-terminal pro-B-type natriuretic peptide level (proportion of geometric mean ratio, 0.18; 95% CI, 0.13-0.24), high-sensitivity cardiac troponin I level (proportion of geometric mean ratio, 0.34; 95% CI, 0.27-0.42), and LVMI (mean difference, -30.8 g/m2; 95% CI, -41.6 to -20.1 g/m2). Safety and tolerability were similar between mavacamten and placebo. No patients experienced LVEF less than 50%. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: Mavacamten significantly improved Valsalva LVOT gradient vs placebo for Chinese patients. All secondary efficacy end points were also improved. Mavacamten was well tolerated with no new safety signals. This study supports the efficacy and safety of mavacamten in diverse populations, including Chinese patients. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05174416.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37639259/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829100731&v=2.17.9.post6+86293ac">37639259</a> | DOI: <a href=https://doi.org/10.1001/jamacardio.2023.3030>10.1001/jamacardio.2023.3030</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37639259</guid><pubDate> Mon, 28 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Zhuang Tian</dc:creator><dc:creator> Liwen Li</dc:creator><dc:creator> Xiaoyan Li</dc:creator><dc:creator> Jian&#39;an Wang</dc:creator><dc:creator> Qing Zhang</dc:creator><dc:creator> Zhanquan Li</dc:creator><dc:creator> Daoquan Peng</dc:creator><dc:creator> Ping Yang</dc:creator><dc:creator> Wei Ma</dc:creator><dc:creator> Fang Wang</dc:creator><dc:creator> Wei Jin</dc:creator><dc:creator> Xiang Cheng</dc:creator><dc:creator> Jing Sun</dc:creator><dc:creator> Yiqun Fu</dc:creator><dc:creator> Cheng Lyu</dc:creator><dc:creator> Shuyang Zhang</dc:creator><dc:date> 2023-08-28</dc:date><dc:source> JAMA cardiology</dc:source><dc:title> Effect of Mavacamten on Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy: The EXPLORER-CN Randomized Clinical Trial</dc:title><dc:identifier> pmid:37639259</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.3030</dc:identifier></item><item><title> Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 56 Results From the VALOR-HCM Randomized Clinical Trial</title><link/> https://pubmed.ncbi.nlm.nih.gov/37639243/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230829100731&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS AND RELEVANCE: Results of this randomized clinical trial showed that in patients with symptomatic obstructive HCM, mavacamten reduced the need for SRT at week 56, with sustained improvements in LVOT gradients and symptoms. Although this represents a useful therapeutic option, given the potential risk of LV systolic dysfunction, there is a continued need for close monitoring. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol. 2023 Aug 28. doi: 10.1001/jamacardio.2023.3342. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> IMPORTANCE: There is an unmet need for novel medical therapies before recommending invasive therapies for patients with severely symptomatic obstructive hypertrophic cardiomyopathy (HCM). Mavacamten has been shown to improve left ventricular outflow tract (LVOT) gradient and symptoms and may thus reduce the short-term need for septal reduction therapy (SRT). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> OBJECTIVE: To examine the cumulative longer-term effect of mavacamten on the need for SRT through week 56. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> DESIGN, SETTING, AND PARTICIPANTS: This was a double-blind, placebo-controlled, multicenter, randomized clinical trial with placebo crossover at 16 weeks, conducted from July 2020 to November 2022. Participants were recruited from 19 US HCM centers. Included in the trial were patients with obstructive HCM (New York Heart Association class III/IV) referred for SRT. Study data were analyzed April to August 2023. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> INTERVENTIONS: Patients initially assigned to mavacamten at baseline continued the drug for 56 weeks, and patients taking placebo crossed over to mavacamten from week 16 to week 56 (40-week exposure). Dose titrations were performed using echocardiographic LVOT gradient and LV ejection fraction (LVEF) measurements. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> MAIN OUTCOME AND MEASURE: Proportion of patients undergoing SRT, remaining guideline eligible or unevaluable SRT status at week 56. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Of 112 patients with highly symptomatic obstructive HCM, 108 (mean [SD] age, 60.3 [12.5] years; 54 male [50.0%]) qualified for the week 56 evaluation. At week 56, 5 of 56 patients (8.9%) in the original mavacamten group (3 underwent SRT, 1 was SRT eligible, and 1 was not SRT evaluable) and 10 of 52 patients (19.2%) in the placebo crossover group (3 underwent SRT, 4 were SRT eligible, and 3 were not SRT evaluable) met the composite end point. A total of 96 of 108 patients (89%) continued mavacamten long term. Between the mavacamten and placebo-to-mavacamten groups, respectively, after 56 weeks, there was a sustained reduction in resting (mean difference, -34.0 mm Hg; 95% CI, -43.5 to -24.5 mm Hg and -33.2 mm Hg; 95% CI, -41.9 to -24.5 mm Hg) and Valsalva (mean difference, -45.6 mm Hg; 95% CI, -56.5 to -34.6 mm Hg and -54.6 mm Hg; 95% CI, -66.0 to -43.3 mm Hg) LVOT gradients. Similarly, there was an improvement in NYHA class of 1 or higher in 51 of 55 patients (93%) in the original mavacamten group and in 37 of 51 patients (73%) in the placebo crossover group. Overall, 12 of 108 patients (11.1%; 95% CI, 5.87%-18.60%), which represents 7 of 56 patients (12.5%) in the original mavacamten group and 5 of 52 patients (9.6%) in the placebo crossover group, had an LVEF less than 50% (2 with LVEF ≤30%, one of whom died), and 9 of 12 patients (75%) continued treatment. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS AND RELEVANCE: Results of this randomized clinical trial showed that in patients with symptomatic obstructive HCM, mavacamten reduced the need for SRT at week 56, with sustained improvements in LVOT gradients and symptoms. Although this represents a useful therapeutic option, given the potential risk of LV systolic dysfunction, there is a continued need for close monitoring. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04349072.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37639243/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829100731&v=2.17.9.post6+86293ac">37639243</a> | DOI: <a href=https://doi.org/10.1001/jamacardio.2023.3342>10.1001/jamacardio.2023.3342</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37639243</guid><pubDate> Mon, 28 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Milind Y Desai</dc:creator><dc:creator> Anjali Owens</dc:creator><dc:creator> Kathy Wolski</dc:creator><dc:creator> Jeffrey B Geske</dc:creator><dc:creator> Sara Saberi</dc:creator><dc:creator> Andrew Wang</dc:creator><dc:creator> Mark Sherrid</dc:creator><dc:creator> Paul C Cremer</dc:creator><dc:creator> Neal K Lakdawala</dc:creator><dc:creator> Albree Tower-Rader</dc:creator><dc:creator> David Fermin</dc:creator><dc:creator> Srihari S Naidu</dc:creator><dc:creator> Nicholas G Smedira</dc:creator><dc:creator> Hartzell Schaff</dc:creator><dc:creator> Ellen McErlean</dc:creator><dc:creator> Christina Sewell</dc:creator><dc:creator> Lana Mudarris</dc:creator><dc:creator> Zhiqun Gong</dc:creator><dc:creator> Kathy Lampl</dc:creator><dc:creator> Amy J Sehnert</dc:creator><dc:creator> Steven E Nissen</dc:creator><dc:date> 2023-08-28</dc:date><dc:source> JAMA cardiology</dc:source><dc:title> Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 56 Results From the VALOR-HCM Randomized Clinical Trial</dc:title><dc:identifier> pmid:37639243</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.3342</dc:identifier></item><item><title> Prevalence and Incidence of Diastolic Dysfunction in Atrial Fibrillation: Clinical Implications</title><link/> https://pubmed.ncbi.nlm.nih.gov/37639219/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230829100731&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: Patients with new-onset AF display high-risk features for HFpEF at diagnosis, emphasizing the importance of evaluating for HFpEF among symptomatic patients with AF. Patients with new-onset AF have accelerated progression in DD over time, which may identify patients with preclinical HFpEF, where preventive therapies may be tested. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Aug 28:ehad592. doi: 10.1093/eurheartj/ehad592. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND AND AIMS: Atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF) are intimately associated disorders. HFpEF may be overlooked in AF when symptoms are simply attributed to dysrhythmia, and incident AF may identify patients at risk for developing diastolic dysfunction (DD). This study aimed to investigate the prevalence and incidence of DD in patients with new-onset AF compared to sinus rhythm (SR). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: Adults with new-onset AF (n = 1,747) or SR (n = 29,623) and no structural heart disease were identified. Propensity-score matching was performed (1:3 ratio) between AF and SR based on age, sex, body mass index, and comorbidities. Severe DD (SDD) was defined by ≥3/4 abnormal parameters (medial e&#39;, medial E/e&#39;, tricuspid regurgitation velocity, left atrial volume index) and ≥moderate (MDD) by ≥2/4. Annualised changes in DD indices were determined. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: New-onset AF was independently associated with SDD (8% vs 3%) and ≥MDD (25% vs 16%). 62% of patients with AF had high-risk H2FPEF scores and 5% had clinically-recognised HFpEF. Over a median follow-up of 3.2 (interquartile range 1.6-5.8) years, DD progressed 2-4-fold more rapidly in those with new-onset AF (p &lt; 0.001 for all). Risk for incident DD was increased i new-onset AF [hazard ratio (95% confidence interval) 2.69 (2.19-3.32) for SDD and 1.73 (1.49-2.02) for ≥MDD]. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: Patients with new-onset AF display high-risk features for HFpEF at diagnosis, emphasizing the importance of evaluating for HFpEF among symptomatic patients with AF. Patients with new-onset AF have accelerated progression in DD over time, which may identify patients with preclinical HFpEF, where preventive therapies may be tested.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37639219/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829100731&v=2.17.9.post6+86293ac">37639219</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad592>10.1093/eurheartj/ehad592</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37639219</guid><pubDate> Mon, 28 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Jwan A Naser</dc:creator><dc:creator> Eunjung Lee</dc:creator><dc:creator> Christopher G Scott</dc:creator><dc:creator> Austin M Kennedy</dc:creator><dc:creator> Patricia A Pellikka</dc:creator><dc:creator> Grace Lin</dc:creator><dc:creator> Sorin V Pislaru</dc:creator><dc:creator> Barry A Borlaug</dc:creator><dc:date> 2023-08-28</dc:date><dc:source> European heart journal</dc:source><dc:title> Prevalence and Incidence of Diastolic Dysfunction in Atrial Fibrillation: Clinical Implications</dc:title><dc:identifier> pmid:37639219</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad592</dc:identifier></item><item><title> Atrial pacing and atrial fibrillation in sinus node dysfunction: a relationship that remains elusive</title><link/> https://pubmed.ncbi.nlm.nih.gov/37638993/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230829100731&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Aug 28:ehad569. doi: 10.1093/eurheartj/ehad569. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37638993/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829100731&v=2.17.9.post6+86293ac">37638993</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad569>10.1093/eurheartj/ehad569</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37638993</guid><pubDate> Mon, 28 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Ratika Parkash</dc:creator><dc:date> 2023-08-28</dc:date><dc:source> European heart journal</dc:source><dc:title> Atrial pacing and atrial fibrillation in sinus node dysfunction: a relationship that remains elusive</dc:title><dc:identifier> pmid:37638993</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad569</dc:identifier></item><item><title> Atrial pacing minimization in sinus node dysfunction and risk of incident atrial fibrillation: a randomized trial</title><link/> https://pubmed.ncbi.nlm.nih.gov/37638973/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230829100731&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: Atrial pacing minimization in patients with sinus node dysfunction does not reduce the incidence of atrial fibrillation. Programming a base rate of 40 bpm without rate-adaptive pacing is associated with an increased risk of syncope or presyncope. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Aug 28:ehad564. doi: 10.1093/eurheartj/ehad564. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND AND AIMS: High percentages of atrial pacing have been associated with an increased risk of atrial fibrillation. This study aimed at evaluating whether atrial pacing minimization in patients with sinus node dysfunction reduces the incidence of atrial fibrillation. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: In a nationwide, randomized controlled trial, 540 patients with sinus node dysfunction and an indication for first pacemaker implantation were assigned to pacing programmed to a base rate of 60 bpm and rate-adaptive pacing (DDDR-60) or pacing programmed to a base rate of 40 bpm without rate-adaptive pacing (DDD-40). Patients were followed on remote monitoring for 2 years. The primary endpoint was time to first episode of atrial fibrillation longer than 6 min. Secondary endpoints included longer episodes of atrial fibrillation, and the safety endpoint comprised a composite of syncope or presyncope. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: The median percentage of atrial pacing was 1% in patients assigned to DDD-40 and 49% in patients assigned to DDDR-60. The primary endpoint occurred in 124 patients (46%) in each treatment group (hazard ratio [HR] 0.97, 95% confidence interval [CI] 0.76-1.25, P=0.83). There were no between-group differences in atrial fibrillation exceeding 6- or 24 hours, persistent atrial fibrillation, or cardioversions for atrial fibrillation. The incidence of syncope or presyncope was higher in patients assigned to DDD-40 (HR 1.71 95% CI 1.13-2.59, P=0.01). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: Atrial pacing minimization in patients with sinus node dysfunction does not reduce the incidence of atrial fibrillation. Programming a base rate of 40 bpm without rate-adaptive pacing is associated with an increased risk of syncope or presyncope.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37638973/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829100731&v=2.17.9.post6+86293ac">37638973</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad564>10.1093/eurheartj/ehad564</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37638973</guid><pubDate> Mon, 28 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Mads Brix Kronborg</dc:creator><dc:creator> Maria Hee Jung Park Frausing</dc:creator><dc:creator> Jerzy Malczynski</dc:creator><dc:creator> Sam Riahi</dc:creator><dc:creator> Jens Haarbo</dc:creator><dc:creator> Katja Fiedler Holm</dc:creator><dc:creator> Charlotte Ellen Larroudé</dc:creator><dc:creator> Andi Eie Albertsen</dc:creator><dc:creator> Lene Svendstrup</dc:creator><dc:creator> Ulrik Hintze</dc:creator><dc:creator> Ole Dyg Pedersen</dc:creator><dc:creator> Ulla Davidsen</dc:creator><dc:creator> Thomas Fischer</dc:creator><dc:creator> Jens Brock Johansen</dc:creator><dc:creator> Jens Kristensen</dc:creator><dc:creator> Christian Gerdes</dc:creator><dc:creator> Jens Cosedis Nielsen</dc:creator><dc:creator> DANPACE II Investigators</dc:creator><dc:date> 2023-08-28</dc:date><dc:source> European heart journal</dc:source><dc:title> Atrial pacing minimization in sinus node dysfunction and risk of incident atrial fibrillation: a randomized trial</dc:title><dc:identifier> pmid:37638973</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad564</dc:identifier></item></channel></rss>